Videos

Hear from the winner of our 2018 Extraordinary Healer award.

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.

Dr. Inga Hofman Zhang from the University of Wisconsin School of Medicine provides an update on treating MDS in children.

Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship between MDS and AML and discusses new and novel treatments for both diseases.

Dr. Antonio Risitano, a hematologist from the Univeristy of Naples, discusses the most current thinking on PNH and its treatment. Questions answered include:

Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis.

Dr. Timothy Olson, a pediatric hematologist at Children's Hospital of Philadelphia, discusses the most current thinking on treatment of children with aplastic anemia. This video was recorded at the Aplastic Anemia and MDS International Foundation's Scientific Symposium in March, 2018.

Dr. Lucy Godley, University of Chicago, and Dr. Luca Malcovati, University of Pavia, discuss the highlights of their session on Genetics and Genomics of Bone Marrow Failure at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. David Margolis, Medical College of Wisconsin, and Dr. Danielle Townsley, MedImmune, discuss the highlights of their session on Treatment Options for Aplastic Anemia at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018. Topics include precision medicine, eltrombopag, and bone marrow transplantation.

Dr. Antonio Risitano, University of Naples and Dr. Regis Peffault DeLatour, Hospital de St. Louis, discuss recent research on treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. Timothy Graubert, Massachusetts General Hospital and Dr. Stephanie Halene, Yale University School of Medicine discuss the highlights of their session on the Biology of Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Here is what one expert says about the right time to start treating relapsed multiple myeloma.

We spoke to ovarian cancer survivors about their advice for women who are newly diagnosed.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

Should cancers that are not traditionally associated with Lynch syndrome or MSI-H status be tested? This expert thinks so.

Audra Moran, president and CEO of the Ovarian Cancer Research Fund Alliance, discusses the support available for caregivers of women with ovarian cancer.

Saketh Guntupalli, M.D., gynecologic oncologist at the University of Colorado Hospital, discusses ways that women can improve intimacy after an ovarian cancer diagnosis.

There are many exciting advances happening in the field of mantle cell lymphoma.

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.

Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.